Ticks are an important but under recognized parasitic threat to cats in many areas of the United States. To characterize the species and stages of ticks most commonly recovered from cats and determine the prevalence of disease agents in the ticks, we conducted a survey of ticks removed from cats at veterinary practices in 18 states from April 2016-June 2017. A total of 796 ticks were submitted from 332 cats from 41 different veterinary practices. A single tick was submitted from the majority of cats, with a mean infestation intensity of 2.4 (range 1-46). The most common tick was Ixodes scapularis, accounting for 422/796 (53.0%) ticks submitted, followed by Amblyomma americanum (224/796; 28.1%) and Dermacentor variabilis (131/796; 16.5%); a few I. pacificus, I. banksi, D. occidentalis, A. maculatum, Rhipicephalus sanguineus, and Otobius megnini were also submitted. A majority of ticks were adults (593/796; 74.5%); females predominated in all adult tick submissions including I. scapularis (277/327; 84.7% female), A. americanum (66/128; 51.6% female), and D. variabilis (75/126; 59.5% female). Immature ticks included 186 nymphs and 17 larvae and were primarily I. scapularis and A. americanum. Adult I. scapularis were most reported to be attached to the dorsal head and neck; A. americanum to the abdomen and perianal region; and D. variabilis to the back and ear. Ticks were collected in every month; the largest number of submissions were in May and June (42.5% of ticks) and October and November (35.9% of ticks). Adults of I. scapularis were most commonly submitted October through December, A. americanum March through June, and D. variabilis May through July. Cats with ticks were predominantly male (58.8%) and altered (76.2%), and most reportedly spent >30% of time outdoors, although 64/294 (21.8%) for which lifestyle estimates were provided were reported to live primarily (≤30% of time outside; n = 54) or entirely (100%; n = 10) indoors. Assay of ticks removed from cats revealed I. scapularis were infected with Borrelia burgdorferi (25.7%) and Anaplasma phagocytophilum (4.4%); A. americanum were infected with Ehrlichia chaffeensis (1.3%); and D. variabilis were infected with spotted fever group Rickettsia spp. (3.1%). No ticks in this study tested positive for Cytauxzoon felis. Pet cats, including those that live primarily indoors, are at risk of tick infestation, potentially exposed to tick-borne disease agents, and would benefit from routine tick control.

After a long bone fracture, dogs may face a long recovery period before full return of limb function. rhBMP-2, in association with good fracture fixation principles, may enhance bone healing in dogs with diaphyseal fractures.

BackgroundA study was conducted to evaluate the effect of indoxacarb applied to cats on adult cat fleas, Ctenocephalides felis, flea egg production and adult flea emergence.MethodsSixteen cats were selected for the study and allocated to two treatment groups. Eight cats were treated with a 19.5% w/v topical spot-on solution of indoxacarb on day 0 and eight cats served as untreated controls. Each cat was infested with 50 fleas on Days -2, 7, 14, 21, 28, 35 and 42. On Days 1, 2, and 3, and at 2 and 3 days after each post treatment reinfestation flea eggs were collected from the pan under each cat cage. Eggs were counted and viability assessed by evaluating adult flea emergence 28 days after egg collection. Three days after treatment or infestation, each cat was combed to remove and count live fleas.ResultsTreatment with indoxacarb provided 100% efficacy following infestations on day -2, 7, 14, 21 and 28 and efficacy was 99.6% following infestations on days 35 and 42. Egg production from indoxacarb treated cats was reduced by 99.9% within 72 hours of treatment. For subsequent infestations no eggs were produced from treated cats from day 8 through day 30. Egg production was still reduced by ≥95.8% through day 45. Indoxacarb treatment also reduced adult flea emergence from eggs for 5 weeks after treatment. The combination of reduction in egg numbers and egg viability from indoxacarb treated cats reduced predicted flea emergence by 100% from days 2 – 31 and 99.9%, 100%, 96.4% and 99.0% on days 37, 38, 44 and 45, respectively.ConclusionsA topical spot-on formulation of indoxacarb provided ≥99.6% efficacy against flea infestations on cats for 6 weeks following a single treatment. Indoxacarb also eliminated or markedly reduced egg production for the entire evaluation period and reduced the viability of the few eggs that were produced from Day 1 through Day 38. Given indoxacarb’s effect on adult fleas, egg production and egg viability; this formulation can interrupt flea reproduction on treated cats for at least 6 weeks after treatment.

BackgroundAn investigation was conducted in West Central Florida, USA to evaluate the efficacy of either topically applied fluralaner or topically applied selamectin to control flea infestations, minimize dermatologic lesions and reduce pruritus in naturally flea infested cats over a 12-week period. When dogs were present in the households, they were treated with either oral fluralaner (if household cats were treated with topical fluralaner) or oral sarolaner (if household cats were treated with topical selamectin).MethodsThirty-one cats in 20 homes were treated once with fluralaner topical solution on day 0 and 18 dogs in these homes were administered a single fluralaner chewable. Twenty-nine cats in 18 homes were treated once monthly with a selamectin topical solution for 3 treatments and 13 dogs in these same homes were treated once monthly for 3 treatments with a sarolaner chewable. Fleas on cats were counted by flea combing, fleas on dogs were estimated using visual area counts and fleas in the indoor premises were assessed using intermittent-light flea traps. Blinded-assessments of feline dermatologic lesions were conducted monthly and pruritus severity was evaluated by pet owners.ResultsA single topical application of fluralaner reduced flea populations on cats by 96.6% within 7 days and by 100% at 12 weeks post-treatment. This efficacy was significantly greater than selamectin treatment where single topical application reduced flea populations on cats by 79.4% within 7 days of initial treatment and 3 consecutive monthly treatments reduced flea populations by 91.3% at the end of 12 weeks. At the end of the 12-week study, all fluralaner-treated cats were flea-free and this was significantly greater than the 38.5% of selamectin treated cats that were flea-free. At the end of the study, fleas were completely eradicated (from cats, dogs and homes) in 95.0% of fluralaner treatment group homes, significantly greater than the 31.3% of selamectin/sarolaner treatment group homes with complete flea eradication. Owner reported cat pruritus was reduced similarly in both treatment groups. Significant improvements in dermatologic lesion scores were achieved by day 30 in fluralaner treated cats and by day 60 in selamectin treated cats.ConclusionsAn in-home investigation in subtropical Florida found that 1 application of topical fluralaner eliminated flea infestations on cats and in homes significantly more effectively than 3 consecutive monthly doses of selamectin.

A single dose of moxidectin SR at a dosage as low as 0.17 mg/kg can safely and reliably confer complete protection against infection after challenge-exposure with D. immitis L3, and protection lasts for at least 180 days. This mode of prophylactic treatment against infection with heartworms effectively eliminates failure of prophylaxis that results from erratic administration of medications designed for monthly administration.